GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » Quick Ratio

CBIO (Crescent Biopharma) Quick Ratio : 3.62 (As of Dec. 2024)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Crescent Biopharma's quick ratio for the quarter that ended in Dec. 2024 was 3.62.

Crescent Biopharma has a quick ratio of 3.62. It generally indicates good short-term financial strength.

The historical rank and industry rank for Crescent Biopharma's Quick Ratio or its related term are showing as below:

CBIO's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful Quick Ratio only.

Crescent Biopharma Quick Ratio Historical Data

The historical data trend for Crescent Biopharma's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma Quick Ratio Chart

Crescent Biopharma Annual Data
Trend Dec24
Quick Ratio
3.62

Crescent Biopharma Quarterly Data
Dec24
Quick Ratio 3.62

Competitive Comparison of Crescent Biopharma's Quick Ratio

For the Biotechnology subindustry, Crescent Biopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescent Biopharma's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Quick Ratio falls into.


;
;

Crescent Biopharma Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Crescent Biopharma's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(34.804-0)/9.614
=3.62

Crescent Biopharma's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(34.804-0)/9.614
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crescent Biopharma  (NAS:CBIO) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Crescent Biopharma Quick Ratio Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescent Biopharma Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.